NCT05847088View on ClinicalTrials.gov

Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:

CompletedOBSERVATIONAL
Enrollment

58

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

March 28, 2023

Study Completion Date

April 4, 2023

Conditions
Diabetic Macular Edema
Interventions
DRUG

Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:

Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.

Trial Locations (1)

12311

Kasr alainy faculty of medicine, Cairo

All Listed Sponsors
lead

Dar El Oyoun Hospital

OTHER